Table 1.
Characteristics of patients receiving vasopressin for PPHN.
| Subject | Birth weight (g) | Sex | Gestational age (weeks) | Diagnosis | Need for therapeutic hypothermia | Need for ECMO | Age at initiation (h) | Initial vasopressin dose (milliunits/kg/h) | Maximum vasopressin dose (milliunits/kg/h) | Duration of vasopressin (h) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 3663 | M | 34.3 | Naphthalene exposure | N/A | N | 47 | 40 | 60 | 212 |
| 2 | 2710 | M | 39 | MAS | N/A | Y (VA) | 17 | 40 | 80 | 5 |
| 3 | 3730 | M | 39 | HIE with pulmonary hemorrhage | Y | N | 21 | 60 | 80 | 157 |
| 4 | 2590 | M | 40.1 | HIE with pneumothorax | Y | Y (VA) | 43 | 40 | 80 | 12 |
| 5 | 3200 | M | 41.1 | MAS | N/A | N | 25 | 60 | 80 | 54 |
| 6 | 2321 | F | 40 | MAS with pneumothorax | N/A | N | 37 | 20 | 20 | 41 |
| 7 | 3145 | F | 39.3 | HIE with MAS | Y | N | 20 | 30 | 80 | 14 |
| 8 | 3940 | M | 38.5 | HIE, COVID-19 exposure | Y | Y (VA) | 28 | 60 | 80 | 7 |
| 9 | 3510 | M | 35.1 | HIE and LV dysfunction | Y | Y (VV) | 30 | 10 | 80 | 20 |
| 10 | 3134 | F | 41 | MAS/HIE/sepsis | Y | Y (VA) | 35 | 20 | 85 | 9.5 |
COVID-19: Coronavirus disease-19; ECMO: extracorporeal membrane oxygenation; F: female; HIE: hypoxic ischemic encephalopathy; LV: left ventricle; M: male; MAS: meconium aspiration syndrome; N: no; N/A: not applicable; PPHN: persistent pulmonary hypertension of newborn; VA: veno-arterial; VV: veno-venous; Y: yes.